Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. In addition to industry players, various academic institutes have filed multiple patents in this domain.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

JANUARY 24, 2021

. “We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND,” said David Main , President and Chief Executive Officer of Notch.

Engineer 52

Engineer Gene Editing Genome Genomics 52

The Pharma Data

NOVEMBER 30, 2020

The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. 1, 2020 09:04 UTC. CEO of Vivlion.

Genome 52

Genome Genomics Licensing Licensing 52

Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genome 52

Genome Genomics RNA Genome Project 52

Drug Discovery World

MARCH 13, 2023

The cell and gene therapy (CGT) landscape has grown significantly in the past year. One example: Zynteglo, a newly approved gene therapy priced at a record-breaking $2.8M ELISA, ELISpot), and cytotoxicity assays, single cell and whole genome sequencing, SNP analysis, and rapid sterility methods to characterise cell therapies.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. This can be achieved by the simultaneous knockout of endogenous TCR genes and the insertion of neoantigen-specific TCRs allowing cells to recognise specific mutations.

DNA 98

DNA Genome Genomics RNA 98

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Financial details of the agreement were not disclosed.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

FEBRUARY 8, 2023

Svea Cheeseman , Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. Data were provided by the Cell and Gene Therapy Catapult (London, UK).

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Drug Discovery World

OCTOBER 12, 2022

This progress includes the expansion of genomic sciences and the ability to design cell bioprocessing platforms for biotherapeutics production that can be used to address previously unmet medical needs. Agilent’s next round of collaboration will look at cell and gene therapy glycan applications. The glycan database . References .

Protein 52

Protein Gene Therapy Antibody Production 52

The Pharma Data

JANUARY 20, 2021

Laboratory Implementation Laboratory reagents for performing the test commercially have been designed and are currently being validated in preparation for regulatory submission to CMS/CLIA with a view to targeting sales in the USA initially. MELBOURNE, Australia, Jan.

Genetics 52

Genetics Reagent Biobanking Production 52

Drug Discovery World

JUNE 6, 2023

In our collateral, we have 56 genes, those are SMBs; we show that we can pick up those SMBs at the same quality if we were doing a separate alone DNA assay. It’s a 1.5 It’s really all driven by the Archer technology. The Archer platform comes with our analysis component that has an output of a variant calling file (VCF).

Protein 52

Protein DNA RNA Research 52